We performed proteomic analysis of neurofibrillary tangles (NFTs) obtained by laser capture microdissection from pyramidal neurons in hippocampal sector CA1 in patients with Alzheimer disease (AD) using liquid chromatography (LC)-mass spectrometry (MS)/MS. We discovered a total of 155 proteins in laser captured NFT's, 72 of which were identified by multiple unique peptides. Of these 72 proteins, 63 had previously unknown association with NFTs; one of these was glyceraldehyde-3-phosphate dehydrogenase (GAPDH). We validated by immunohistochemistry that GAPDH colocalized with the majority of NFTs as well as plaque-like structures in AD brain and was coimmunoprecipitated by antibodies to abnormal forms of tau in AD, but not tau from AD temporal cortex. Characterization of GAPDH showed that it, along with phosphorylated tau and Aβ peptides, was present in detergent-insoluble fractions from AD temporal cortex but not from age-matched controls. These data are the first proteomic investigation of NFTs. Moreover, our results validate this approach by demonstrating that GAPDH, a glycolytic and microtubule binding protein, not only co-localized to NFTs and immunoprecipitated with PHF-tau, but also is one of the few proteins known to undergo conversion to a detergent-insoluble form in AD.
other hallmark histopathologic feature of AD. A hyperphosphorylated abnormal form of the microtubule binding protein tau, paired helical filament (PHF)-tau, has been identified as the major protein component of NFTs (3) . Inheritance of mutations in the gene for tau is associated with a related form of dementia that shares with AD NFT but not SP formation (4) .
Limited analysis of proteins associated with NFTs has given important new clues to the pathogenesis of neurodegenerative diseases. For example, apolipoprotein (apo) E was colocalized to NFTs and SPs prior to genetic association studies that linked inheritance of the ε4 allele of APOE with increased risk of late-onset familial and sporadic AD (5) . In addition, α-synuclein was identified as the major non-amyloid component (NAC) of SPs using traditional techniques prior to discovering that this protein is central to a number of neurodegenerative diseases now called α-synucleinopathies (6) . In contrast to a previous proteomics study of contents of SPs (7), a comprehensive assessment of NFT protein constituents is yet to be reported but likely would inform us about protein-protein interactions important in AD pathogenesis. Here we undertook a proteomic analysis of laser captured microdissected (LCM) NFTs and then pursued immunohistochemical and biochemical validation and characterization of selected proteins with previously unknown association with NFTs.
MATERIALS AND METHODS

Laser capture microdissection (LCM)
Blocks of fresh hippocampus obtained at autopsy were embedded in Tissue-Tek Optimum Cutting Temperature compound (Sakura Finetek, Torrance, CA), frozen, and stored at -80°C. Frozen sections were cut at 10 µm thickness using a Leica CM 3050 cryostat and mounted on PALM Membrane Slides (Microlaser Technologies AG, Bernried, Germany). Sections were fixed in cold acetone for 10 min and permeabilized in 0.1% Triton X-100 for 10 min. After blocking with 3% H 2 O 2 and 5% nonfat milk, sections were incubated with mouse monoclonal anti-tau antibody (Tau-2, Sigma, St. Louis, MO; 1:250) for 1 h at room temperature. Sections were rinsed extensively and subsequently incubated with biotinylated horse anti-mouse antibody (Vector Laboratories, Burlingame, CA; 1:200) at room temperature for 45 min. The biotinylated secondary antibody was detected by avidin-biotin complex (ABC kit, Vector Laboratories, used at 1:100) and visualized with diaminobenzidine (Sigma). Sections were counterstained with hematoxylin (Sigma) and dehydrated in a series of graded ethanol and stored at -80°C until used.
Laser capture microdissection was performed with a method described previously by others (7, 8) . Briefly, frozen tissue sections were thawed at room temperature for 40 s and NFTs were stained with anti-tau antibody as described above. Tau-2-immunoreactive structures with the size and shape of NFTs in CA1 sector of hippocampus were subjected to LCM using PALM Microbeam technology under ×40 magnification. For each of two experiments, ~500 NFTs were collected from each of 4 different autopsies, for a total of ~2000 NFTs that were pooled for proteomic analysis.
Proteomic analysis using LC/MS-MS
NFTs were extracted with 70% formic acid and sonicated gently for 1 min. After vacuum centrifugation, samples were transferred to a NH 4 HCO 3 buffer and reduced with iodoacetamide before being subjected to trypsin digestion overnight at 37°C as described previously (9, 10) . The amount of protein in samples and completeness of digestion were estimated by silver staining aliquots of NFT proteins electrophoresed in Tris-SDS gels and compared with BSA standards prepared in parallel. Digested peptides were purified with a C18 solid phase extraction column (Oasis R MCX, Milford, MT), and separated by a two dimensional microcapillary high performance LC system, which integrates a strong cation-exchange (SCX) column with two alternating reversed-phase C 18 columns (10 cm×180 µm), followed by analysis with tandem MS (ThermoFinnigan, San Jose, CA). Settings for the LC-MS/MS were as follows: 4 fractions were eluted from SCX using a binary gradient of 2-90% solvent D (1.0 M ammonium chloride and 0.1% formic acid in 5% acetonitrile) vs. solvent C (0.1% formic acid in 5% acetonitrile). Each fraction was injected onto a reverse-phase column automatically with the peptides being resolved using a 200 min binary gradient of 5-80% solvent B (acetonitrile and 0.1% formic acid) vs. solvent A (0.1% formic acid in water). A flow rate of 160 µl/min was used. To determine the amino acid sequence, the mass spectrometer operated in a data-dependent MS/MS mode (a fullscan mass spectrum is followed by a tandem MS), where the precursor ion was selected "on the fly" from the previous scan. An m/z ratio for an ion that had been selected for fragmentation was placed in a list and dynamically excluded for 3 min from further fragmentation. Proteins from the mixture were later identified automatically using the computer program SEQUEST, which searched tandem mass spectra against the International Protein Database. Next, the sensitivity and specificity of protein identification were determined by PeptideProphet and ProteinProphet software. All of these methods have been used in our laboratories previously (9, 10).
Immunhistochemistry using fixed tissue
Hippocampal tissue that had been fixed in formalin and embedded in paraffin was cut at 8 microns, and sections were mounted on glass slides. Sections were deparaffinized in xylene and rehydrated in graded ethanol. After microwave antigen retrieval and treatment with 3% H 2 O 2 and 5% nonfat dry milk, sections were incubated with primary antibody to tau (Tau-2; 1:500), clathrin (mouse anti-clathrin monoclonal antibody, Chemicon, Temecula, CA; 1:100), UCH-L1 (goat polyclonal anti-UCH-L1, Chemicon; 1:100), or GAPDH (mouse monoclonal anti-GAPDH, Chemicon; 1:500) at room temperature for 2 h. Biotinylated secondary antibody application and chromogen development were carried out as described above for LCM NFTs, with rabbit antigoat antibody (Vector Laboratories; 1:200) used for UCH-L1.
Western blotting
Samples were diluted with reducing Laemmli buffer, subjected to electrophoresis in 4-15% gradient SDS-polyacrylamide (GAPDH and tau) or 16.5% tricine (Aβ) gels and transferred to PVDF membranes. Membranes were blocked with 5% milk and blotted with anti-GAPDH (described above; 1:2000), rabbit polyclonal anti-phosphotau (P-tau-199/202, Sigma; 1:1000) or mouse monoclonal anti-Aβ protein (4G8, Signet Laboratories, Dedham, MA; 1:500) followed by anti-mouse or anti-rabbit IgG-HRP (Amersham Pharmacia, Piscataway, NJ; 1:7500-10,000). Enhanced chemiluminescence (Amersham Pharmacia) was used for protein band visualization.
Immunoprecipitation of PHF-tau or tau
Immunoprecipitaion was performed as described previously with minor changes (9) . Homogenates of human hippocampus (1 mg/ml protein) in lysis buffer (150 mM NaCl, 50 mM Tris, 1% NP-40 and protease inhibitor cocktail from Sigma, pH 7.4) were incubated with 20 µl of mouse monoclonal antibody PHF-1 (generous gift of Peter Davies, Albert Einstein Medical School) or 5 µl of rabbit anti-tau (DAKO, Carpinteria, CA) for 2 h at 4°C and further incubated with 25 µl of protein A/G agarose beads (Santa Cruz, San Diego, CA) overnight at 4°C. The pull-down was solubilized in sample buffer, separated by SDS-PAGE, and immunoblotted with anti-GAPDH as described above.
Extraction of sarkosyl-insoluble proteins
Sarkosyl-insoluble proteins from frozen temporal cortex were extracted as described previously (11) with minor modifications. In brief, to each 200 mg tissue sample was added 2 ml ice-cold buffer A (10 mM Tris, 1 mM EGTA, 1 mM DTT, 10% sucrose, pH 7.5). Tissues were sonicated briefly with a Branson model 250 probe sonifier (25% maximum output for 30 s), then separated by centrifugation at 26,500 × g for 15 min at 4°C. After removal of Supernatant A, the resulting pellet was extracted by sonication as before in ice-cold buffer A + 1% Triton X100, followed by centrifugation at 386,000 × g for 20 min at 4°C. Supernatant B was removed, the pellet was extracted twice at room temperature by sonication in buffer A + 1% N-laurylsarkosyl, and separated by centrifugation at 386,000 × g for 20 min at 20°C. Supernatant C was collected from the first of these extractions, and the pellet was sonicated twice in water and subjected to centrifugation at 386,000 × g for 20 min at 20°C to remove residual detergents. The resulting pellet was extracted by sonication in 70% formic acid, and Supernatant D was collected after a final centrifugation at 386,000 × g for 20 min at 20°C and dried by vacuum centrifugation. All supernatant fractions were subsequently normalized to equal volumes with the addition of Laemmli sample buffer containing 50 mM DTT, boiled for 5 min, and equal volumes of each were electrophoresed and Western blotted as described above.
RESULTS
Discovery
Proteomic analysis of tryptic digests of LCM NFTs from AD brain using LC/MS-MS
NFTs were visualized by anti-tau immunohistochemistry and obtained by laser capture microdissection (LCM) from pyramidal neurons in hippocampal sector CA1 (Fig. 1) , solubilized in formic acid with sonication, digested with trypsin, the resulting peptides analyzed by LC/MS-MS, and the data analyzed by SEQUEST against the International Protein Index (IPI) database followed by probability calculation with PeptideProphet and ProteinProphet. We identified a total of 155 proteins in laser captured NFTs, 72 of which were identified by multiple unique peptides (Appendix). Of the 72, 63 proteins had no previously known association with NFTs. Functional class distribution of these 72 proteins is shown in Fig. 2 . Expected proteins, such as tau, apolipoprotein E (identified by single peptide), and α-synuclein were identified in our proteomic screen, confirming the ability of this approach to identify NFT-associated proteins.
Validation: GAPDH co-localizes to most NFTs and binds to PHF-tau in vivo
Given the limitations of LCM and the need to validate proteins identified in proteomic database searches, we set out to confirm selected candidate proteins by immunohistochemistry in sections of hippocampus from AD patients (n=3) and age-matched controls (n=2). We selected three proteins identified by multiple unique peptides in our proteomic study that had no known prior association with NFTs and that had commercially available antibodies; these were clathrin, ubiquitin carboxyl-terminal hydrolase isozyme L1 (UCH-L1), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Both clathrin and UCH-L1 showed widespread immunolocalization in gray matter to both cell soma and neuropil, demonstrating that these proteins were not specifically localized to NFTs. In contrast, GAPDH co-localized with the majority of NFTs as well as plaque-like structures in AD hippocampus (Fig. 3) ; no immunoreactive structures were present in controls. As biochemical validation, we confirmed that GAPDH was detectable in LCM NFTs by Western blot and proteolyzed by trypsin (Fig. 3) . Thus, our immunohistochemistry and immunoblot experiments validated our proteomics investigation that identified GAPDH as a protein component of NFTs and suggested that GAPDH may also be a component of senile plaques (SPs). Others have shown that some antibodies to Aβ peptides, the major protein constituent in senile plaques of AD, cross-react with GAPDH, raising the possibility that the converse may be true, viz., GAPDH antibody may have recognized Aβ peptides. We ruled this out using Western blots to show that our GAPDH antibody did not react with Aβ peptides in homogenates from AD temporal cortex (see Fig. 4 ). In addition, immunoprecipitation of homogenates from AD hippocampus with PHF-1, that recognizes an abnormal form of tau in AD, co-precipitated GAPDH; immunoprecipitation with tau antisera did not co-precipitate GAPDH (Fig. 3) ; stripping and reprobing of these blots showed both antibodies immunoprecipitated tau. Because PHF-tau is also present in pathologic structures other than NFTs, e.g., dystrophic neurites in SPs, these results do not prove localization of GAPDH to NFTs. Nevertheless, in combination with our immunohistochemistry and immunblotting results, these findings strongly support a direct interaction between GAPDH and PHF-tau in NFTs in vivo.
Characterization: GAPDH accumulates in the detergent-insoluble fraction in AD brain but not in controls
A key pathogenic event in AD and several other neurodegenerative diseases is the accumulation of abnormal forms of proteins that acquire new biochemical characteristics; in the case of AD this is widely determined as the formation of detergent (sarkosyl)-insoluble but at least partially formic acid-soluble PHF-tau and Aβ. Serial extractions of temporal cortex were prepared from 5 patients who died of AD (age=80±1 y, 3 women, PMI=4.3, median Braak stage of VI) and 4 agematched controls (age=84±2 y, 1 woman, PMI=4.7 h). Western blots showed the expected serial extraction of Aβ and PHF-tau with abundant Aβ and PHF-tau immunoreactivity in the sarkosylinsoluble/formic acid soluble fraction in all AD patients but none of the controls (Fig. 4) . Remarkably, GAPDH was also present in the sarkosyl-insoluble/formic acid-soluble fraction only from AD patients (Fig. 4) .
DISCUSSION
NFTs are hallmark pathologic inclusions formed in AD that are closely associated with dementia and are composed primarily of PHF-tau. Several other proteins have been co-localized to NFTs; however, we are unaware of any unbiased assessment of NFT constituents. We hypothesized that unbiased discovery of NFT constituent proteins may provide new insight into protein-protein interactions important to AD pathogenesis and perhaps other neurodegenerative diseases, like the previous discoveries that co-localized apoE to NFTs and SPs and α-synuclein as the nonamyloid component of SPs (12, 13) . Here we tested this hypothesis by LC/MS/MS proteomic analysis of LCM NFTs followed by characterization of selected proteins so identified. Our novel findings were (i) discovery of 63 proteins in LCM NFTs that were identified by multiple unique peptides that had no prior association with NFTs, (ii) validation by immunohistochemistry that one of three proteins selected from among these 63, GAPDH, co-localized to most NFTs and immunoprecipated with PHF-tau from AD temporal cortex, and (iii) characterization of GAPDH as one of the few reported proteins whose conversion to a detergent-insoluble state is associated with AD.
Both LCM and peptide database-derived protein identification have limitations, thus it was critical to confirm that proteins identified by proteomic analysis of LCM material were indeed associated with NFTs. This is typically achieved by immunochemical detection; however, this approach is limited by availability of antibodies. As an initial validation, we investigated 3 proteins contained in our list of 63 proteins that had commercially available antibodies. Of these 3 proteins, only 1 was relatively selectively localized to NFTs; this is not to say that the other 2 proteins were not localized to NFTs but rather that these were diffusely present throughout gray matter in AD patients and controls and so cannot be clearly interpreted as coming from LCM NFTs or small amounts of co-captured tissue.
GAPDH, unequivocally associated with NFTs and PHF-tau in our study, was initially described as a glycolytic enzyme that is now appreciated to have pleotrophic actions independent of energy metabolism that may influence neurodegeneration; these include roles in membrane fusion and endocytosis, microtubule binding, regulation of mRNA, and nuclear translocation in apoptosis (14) . Others have immunohistochemically co-localized GAPDH to Lewy bodies in Parkinson disease and proteins containing trinucleotide repeat expansions, such as huntingtin (15) . With respect to AD, GAPDH has been shown to bind amyloid precursor protein in vitro, and cultured human fibroblasts from AD patients have abnormal subcellular distribution of GAPDH (16). Although we discovered many NFT-associated proteins that are yet to be evaluated, our results with GAPDH highlight the power of unbiased proteomic techniques in pursuit of interacting proteins that may influence the pathogenesis of neurodegenerative diseases, and show that GAPDH should be included with those few proteins that accumulate in inclusions and shift to a detergent-insoluble form in AD.
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